A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis (Q82207899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

15 January 2020

main subject

1 reference

inferred from title

systemic mastocytosis

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Cynthia E. Dunbar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

9

Metcalfe DD

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Nakamura R

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Chakrabarti S

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Robyn J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Bahceci E

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Greene A

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Childs R

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Barrett AJ

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

353-358

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16400343%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

cites work

Systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Mastocytosis: molecular mechanisms and clinical disease heterogeneity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Diagnosis and treatment of systemic mastocytosis: state of the art.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Cladribine therapy for systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Treatment of systemic mast-cell disease with cladribine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Optimizing treatment of chronic myeloid leukemia: a rational approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021

Imatinib as a paradigm of targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705245

7 January 2021